Register to get unlimited access to all of Citywire’s fund manager database. Registration is free and only takes a minute.

BlackRock Health Sciences Opportunities Port;Inv A

Ranked 22 out of 140 in - Pharmaceuticals & Health Care over 12 months
All calculations are in USD unless stated

Managed by

Tom Callan

Tom Callan was born in the USA in 1959. He graduated from Boston College with a BA degree in economics. Tom started his career at PNC Bank in 1988 where he was a personal trust portfolio manager. In 1992 he worked as a healthcare and international equity analyst at PNC Asset Management Group. Tom joined BlackRock in 1998 where he is currently a portfolio manager and team leader. He has over 22 years of investment experience and is a Chartered Financial Analyst. Tom is a also a member of the Financial Analysts of Philadelphia. Outside of fund management he enjoys cycling, architecture, visual arts and international travel.

Erin Xie

Erin Xie, PhD, managing director, is a member of the Fundamental Equity division of BlackRock's Alpha Strategies Group. She is a member of BlackRock's Global Opportunities team. Erin is the team's lead portfolio manager for the healthcare sector, product manager for Health Sciences equity portfolios and a member of the team's Investment Strategy Group. Her service with the firm dates back to 2001, including her years with State Street Research & Management (SSRM), which merged with BlackRock in 2005. At SSRM, Erin was a senior vice president and portfolio manager responsible for managing the State Street Health Sciences Fund. Prior to joining State Street Research in 2001, she was a research associate with Sanford Bernstein covering the pharmaceutical industry from 1999. From 1994 until 1997, Erin was a post-doctoral research scientist at Columbia University. She earned a BSc in Chemistry from Beijing University in 1988, a PhD in Biochemistry from the University of California, Los Angeles, in 1993 and an MBA from the Massachusetts Institute of Technology Sloan School of Management in 1999.

Objective

The Fund seeks to provide long-term growth of capital. The Fund invests at least 80% of total assets in securities of companies in health sciences and related industries.

Showing fund performance globally. You can view performance in individual jurisdictions.

Performance

Pharmaceuticals & Health Care over : 31/03/2016 - 31/03/2017

Total Return

Quarterly Performance

to 31/03/2017 Annual Q1 Q2 Q3 Q4
2017 10.4%
2016 -6.1% -9.8% 7.2% 2.7% -5.5%
2015 11.0% 10.2% 4.7% -11.2% 8.4%
2014 28.9% 5.5% 5.0% 6.4% 9.3%
2013 44.2% 17.5% 1.7% 11.6% 8.1%
2012 18.4% 10.3% 0.8% 6.3% 0.2%
2011 6.0% 7.1% 5.0% -12.1% 7.2%
2010 7.2% 6.0% -11.0% 7.9% 5.3%
2009 27.3% -4.4% 10.8% 11.6% 7.7%
2008 -19.3% -9.0% 1.8% 1.2% -14.0%
2007 20.4% 2.8% 4.7% 6.9% 4.5%
2006 8.2% 5.7% -5.7% 6.6% 1.9%
2005 16.8% -5.7% 10.3% 9.1% 3.0%
2004 14.6% 5.7% 0.7% -3.5% 11.4%
2003 66.6% 1.5% 34.7% 9.3% 11.5%
2002 -22.9% -6.5% -15.2% -10.8% 8.8%
2001 3.5% -14.3% 15.1% -8.5% 14.7%
2000 55.2% 12.8% 19.8% 18.9% -3.4%

Month by Month Performance

Returns Vs Risk

Registered For Sale In

  1. United States

Fund Info

  • Launch date21/12/1999
  • Share Class size2,365Mn
  • Base currencyUSD
  • ISIN US0919375735

Purchase Info

  • Min. initial investment1,000
  • Min. regular additional investment50

Charges

  • Annual management0.68%
  • Initial investment0

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in USD).